Skip to content
Contact
About PORTAL
Our Team
Our Work
Innovation Incentives and Competition
Regulation and Clinical Evidence
Price, Value, and Access
Search Our Library
Congress Should Remove the Rare Disease Carve-Out From Medicare Drug Price Negotiation, Not Expand It
HOME
/
Commentary & Opinion
/
Congress Should Remove the Rare Disease Carve-Out From Medicare Drug Price Negotiation, Not Expand It